Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC?
Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC?
复制标题
使用直接抗病毒药物清除 HCV 后的免疫重建：对 HCC 患者的潜在后果？
DOI：
10.1097/tp.0000000000001606
复制
发表时间：
2017
期刊：
影响因子：
6.2
通讯作者：
Protzer U
中科院分区：
文献类型：
--
作者：
Werner JM;Adenugba A;Protzer U
最近推出的全口服直接作用抗病毒药物（DAA）治疗彻底改变了慢性丙型肝炎病毒感染患者的护理。由于具有不同肝病阶段的患者已经获得了巨大的成功，包括那些等待肝移植的患者，因此治疗也已扩展到肝细胞癌患者。在接受含干扰素方案治疗的代偿性丙型肝炎患者中进行的观察性研究表明，持续病毒学应答后，肝细胞癌的发生率明显降低。然而，最近发表的2项研究报告了DAA药物清除病毒后肿瘤复发率和发生率显著增加。在过去的几十年中，已经确定丙型肝炎病毒持续感染期间的慢性抗原刺激与几种免疫细胞群体（如自然杀伤细胞和病毒特异性T细胞）的持续激活和功能受损相关。因此，本文综述的重点是最近的研究评估DAA治疗后，在肝癌发生的免疫反应的背景下，慢性丙型肝炎病毒感染患者的适应性和先天免疫细胞群的恢复。
Recent introduction of all-oral direct-acting antiviral (DAA) treatment has revolutionized care of patients with chronic hepatitis C virus infection. Because patients with different liver disease stages have been treated with great success including those awaiting liver transplantation, therapy has been extended to patients with hepatocellular carcinoma as well. From observational studies among compensated cirrhotic hepatitis C patients treated with interferon-containing regimens, it would have been expected that the rate of hepatocellular carcinoma occurrence is markedly decreased after a sustained virological response. However, recently 2 studies have been published reporting markedly increased rates of tumor recurrence and occurrence after viral clearance with DAA agents. Over the last decades, it has been established that chronic antigen stimulation during persistent infection with hepatitis C virus is associated with continuous activation and impaired function of several immune cell populations, such as natural killer cells and virus-specific T cells. This review therefore focuses on recent studies evaluating the restoration of adaptive and innate immune cell populations after DAA therapy in patients with chronic hepatitis C virus infection in the context of the immune responses in hepatocarcinogenesis.
登录
查看更多内容
影响因子：
7.2
作者：
Lugade AA;Kalathil S;Miller A;Iyer R;Thanavala Y
通讯作者：
Thanavala Y
影响因子：
17.1
作者：
Bohne, Felix;Londono, Maria-Carlota;Sanchez-Fueyo, Alberto
通讯作者：
Sanchez-Fueyo, Alberto
DOI：
10.1016/s0015-6264(78)80335-6
发表时间：
1986
期刊：
The New Zealand medical journal
影响因子：
--
作者：
D. Woodfield
通讯作者：
D. Woodfield
影响因子：
29.4
作者：
Dolganiuc, Angela;Norkina, Oxana;Szabo, Gyongyi
通讯作者：
Szabo, Gyongyi
DOI：
10.1056/nejmra1213651
发表时间：
2013-05-16
期刊：
The New England journal of medicine
影响因子：
--
作者：
Liang TJ;Ghany MG
通讯作者：
Ghany MG